Immunocytochemical p63 expression discriminates between primary cutaneous follicle centre cell and diffuse large B cell lymphoma‐leg type, and is of the TAp63 isoform

Abstract

Functional studies are required to clarify the significance of p63 overexpression in primary cutaneous B cell lymphoma.

A Case of p63 Positive Diffuse Large B Cell Lymphoma of the Bladder

“…P63 is positive in a significant amount of DLBCL cases, with percentages ranging from 15 to 70% depending upon the study examined [3–7]. The correlation between p63 expression and overall survival remains unclear; however, studies have shown a correlation of p63 with a high proliferative index, suggesting its involvement with DLBCL tumor progression [5, 6]. …”

“…These isoforms, among other functions, are responsible for the regulation and differentiation of stratified epithelial cells. Changes in isoform expression lead to proliferation and differentiation of these tissues and also play an active role in neoplasia [5, 8]. While p53 is widely acknowledged as a tumor suppressor gene and its mutations are responsible for tumor progression, the role of p63 as a cancer oncogene continues to be studied.…”

“…The ΔNp63 isoform lacks this N-terminal domain and likely has a dominant-negative effect on p53 [8]. RT-PCR and Western Blot analysis of various cancer cell lines reveal that the ΔNp63 isoform is overexpressed in squamous cell carcinomas of the head, neck, and lung, while overexpression of the TAp63 isoform appears to be responsible for lymphoid malignancy [5, 8]. This implies a tumor-promoting role, though the exact mechanism is not clear.…”

“…No consistent correlation was found between the immunohistochemical expression of p63 and expression of CD10, BCL-2, BCL-6, or p53 [7]. However, studies by Hedvat et al found a correlation between p63 expression and Ki-67 proliferative index, suggesting a role in DLBCL tumor progression [5, 6]. Despite this finding, investigations into the effect of p63 on prognosis have found conflicting results.…”

“…Two studies by Park et al suggest a decreased survival with p63 overexpression in cases of DLBCL [3, 4]; however, another study by Hallack Neto et al evaluating cases of high-risk diffuse large B cell lymphoma found better disease-free survival in patients with p63-positive tumors than those that were p63-negative [7]. Additional studies reveal no significant correlation with p63 expression and overall survival, further complicating the picture [5, 6]. It remains likely that these studies used different parameters to define survival; therefore, a larger, more comprehensive study is warranted to truly evaluate the role of p63 expression on prognosis in DLBCL.…”